GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » EV-to-FCF

Sutro Biopharma (FRA:S09) EV-to-FCF : -0.42 (As of Jun. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sutro Biopharma's Enterprise Value is €46.3 Mil. Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-110.4 Mil. Therefore, Sutro Biopharma's EV-to-FCF for today is -0.42.

The historical rank and industry rank for Sutro Biopharma's EV-to-FCF or its related term are showing as below:

FRA:S09' s EV-to-FCF Range Over the Past 10 Years
Min: -126.91   Med: -1.72   Max: 32.56
Current: -0.51

During the past 8 years, the highest EV-to-FCF of Sutro Biopharma was 32.56. The lowest was -126.91. And the median was -1.72.

FRA:S09's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs FRA:S09: -0.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Sutro Biopharma's stock price is €3.82. Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.747. Therefore, Sutro Biopharma's PE Ratio for today is At Loss.


Sutro Biopharma EV-to-FCF Historical Data

The historical data trend for Sutro Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma EV-to-FCF Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -2.13 -8.67 -5.66 -41.93 0.69

Sutro Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 1.19 0.68 0.69 -0.57

Competitive Comparison of Sutro Biopharma's EV-to-FCF

For the Biotechnology subindustry, Sutro Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's EV-to-FCF falls into.



Sutro Biopharma EV-to-FCF Calculation

Sutro Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=46.265/-110.36
=-0.42

Sutro Biopharma's current Enterprise Value is €46.3 Mil.
Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-110.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sutro Biopharma  (FRA:S09) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sutro Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.82/-1.747
=At Loss

Sutro Biopharma's share price for today is €3.82.
Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.747.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sutro Biopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma (FRA:S09) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines